These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 11811390)
1. Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors. Lüscher TF; Spieker LE; Noll G; Cosentino F J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S3-11. PubMed ID: 11811390 [TBL] [Abstract][Full Text] [Related]
2. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Ruschitzka FT; Lüscher TF Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622 [TBL] [Abstract][Full Text] [Related]
3. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Gupta S; Wright HM Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089 [TBL] [Abstract][Full Text] [Related]
4. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Ignarro LJ; Byrns RE; Trinh K; Sisodia M; Buga GM Nitric Oxide; 2002 Sep; 7(2):75-82. PubMed ID: 12223176 [TBL] [Abstract][Full Text] [Related]